Kyverna therapeutics and stanford university agree to evaluate kyv-101 in patients with non-relapsing and progressive forms of multiple sclerosis

The investigator-initiated trial will assess the safety, tolerability, and clinical activity of kyv-101, a fully human anti cd19 car t-cell therapy in up to 12 study participants the clinical study will be supported by cutting edge correlative studies funded through a parallel research collaboration between kyverna and stanford university the agreements further expand the scale of ongoing clinical studies assessing the potential therapeutic effects of kyv-101 in multiple diseases and locations around the world emeryville, calif. , march 7, 2024 /prnewswire/ -- kyverna therapeutics, inc. (kyverna), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases, today announced the signature of a collaboration agreement with stanford university to allow the use of kyv-101, an investigational, anti-cd19 car t-cell therapy in an open label, phase 1 investigator-initiated trial (iit) in nine to twelve adult subjects with non-relapsing and progressive forms of multiple sclerosis.
KYTX Ratings Summary
KYTX Quant Ranking